The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States…
June 20-21, 2018
Deadline for registration:
Non-US Citizens: May 16, 2018
US Citizens: June 11, 2018
Registration is NOT required to watch the live meeting webcast or to listen via telephone.
Complete list of ACIP recommendations published in the MMWR.
Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
GRADE (Grading of Recommendations Assessment, Development & Evaluation)
Find tables referenced in ACIP recommendations published in MMWR and learn about GRADE.
General Committee-related Information
Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
Nominations for future vacancies on ACIP
Procedure for nomination of candidates for ACIP membership.
- Nominations for future vacancies on ACIP
Journal articles about the ACIP.
ACIP Guidance for Economics Studies
Procedures for review of economic analyses to be presented to the ACIP.
ACIP Guidance for Vaccine Recommendations for Pregnant & Breastfeeding Women
Guiding principles for development of ACIP recommendations for vaccination of pregnant and breastfeeding women.
- ACIP Vaccine Acronyms
This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?
On November 9, 2017, FDA approved a new hepatitis B vaccine, HEPLISAV-B®, for use in adults 18 years of age and older. HEPLISAV-B® is the first licensed vaccine using a CpG adjuvant* and is administered as two doses given one month apart. Further details on this vaccine’s approval can be found at Vaccines Licensed for Use in the United States.
*Cytosine phosphoguanine (CpG) 1018 adjuvant
February 2018 Meeting Recommendations
ACIP approved the following recommendations by majority vote at its February 2018 meeting:
- For the 2018-2019 influenza season, immunization providers are recommended to administer any licensed, age-appropriate influenza vaccine (IIV, RIV, or LAIV). LAIV4 is an option for influenza vaccination for persons for whom it is otherwise appropriate.
- HEPLISAV-B (HepB-CpG) is a Hepatitis B vaccine that may be used to vaccinate persons aged 18 years and older against infection caused by all known subtypes of hepatitis B virus.
- Hepatitis A vaccines should be administered for post-exposure prophylaxis for all persons aged ≥12 months.
- In addition to hepatitis A vaccine, immune globulin may be administered to persons aged >40 years depending on the providers’ risk assessment.
- Hepatitis A vaccine should be administered to infants aged 6-11 months traveling outside the United States when protection against hepatitis A is recommended.
- ACIP adopted an Evidence to Recommendation framework to support ACIP decision making.
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.
- Page last reviewed: April 15, 2016
- Page last updated: May 10, 2018
- Content source: